Showing 19,441 - 19,460 results of 125,008 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( a ((point decrease) OR (mean decrease)) ))', query time: 1.20s Refine Results
  1. 19441
  2. 19442
  3. 19443
  4. 19444
  5. 19445
  6. 19446

    Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a... by Dario Giugliano (10218354)

    Published 2021
    “…At 6 months, patients experienced similar reduction in HbA1c level (-0.6 ± 0.8, -0.6 ± 0.8, -0.7 ± 0.9%, mean ± SD, respectively, noninferiority P < 0.001 vs BBI) and the proportion of patients with HbA1c ≤7.5% was also similar (34%, 28% and 27%, respectively, P = 0.489). …”
  7. 19447
  8. 19448
  9. 19449
  10. 19450
  11. 19451
  12. 19452

    Effect of Cytosolic pH on Inward Currents Reveals Structural Characteristics of the Proton Transport Cycle in the Influenza A Protein M2 in Cell-Free Membrane Patches of <i>Xenopus... by Mattia L. DiFrancesco (364045)

    Published 2014
    “…<div><p>Transport activity through the mutant D44A of the M2 proton channel from influenza virus A was measured in excised inside-out macro-patches of <i>Xenopus laevis</i> oocytes at cytosolic pH values of 5.5, 7.5 and 8.2. …”
  13. 19453
  14. 19454

    Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension by Tetsuo Asaki (1366140)

    Published 2015
    “…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
  15. 19455

    Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension by Tetsuo Asaki (1366140)

    Published 2015
    “…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
  16. 19456
  17. 19457
  18. 19458

    Mean ± SEM FPKM values measured for differentially expressed genes. by Sarah W. Keenan (765990)

    Published 2015
    “…The mean FPKM values, P-values, sequence length, and exon density for each of these genes can be found in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0131669#pone.0131669.s005" target="_blank">S1</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0131669#pone.0131669.s007" target="_blank">S3</a> Tables.…”
  19. 19459

    Effects of the adenosine A<sub>2A</sub> antagonist MSX-3 on PROG/chow performance. by Patrick A. Randall (302096)

    Published 2013
    “…<p>On measures of lever pressing, mean (±SEM) total lever presses (A) and maximum ratio achieved (B) were both significantly increased at doses of 1.0 and 2.0 mg/kg while active lever time (measured in seconds, C) was only increased at a dose of 2.0 mg/kg. …”
  20. 19460